CO2017004271A2 - Un proceso para reducir la espumación de composiciones sólidas de vacuna al mezclarse con un diluente líquido, y composiciones de las mismas - Google Patents

Un proceso para reducir la espumación de composiciones sólidas de vacuna al mezclarse con un diluente líquido, y composiciones de las mismas

Info

Publication number
CO2017004271A2
CO2017004271A2 CONC2017/0004271A CO2017004271A CO2017004271A2 CO 2017004271 A2 CO2017004271 A2 CO 2017004271A2 CO 2017004271 A CO2017004271 A CO 2017004271A CO 2017004271 A2 CO2017004271 A2 CO 2017004271A2
Authority
CO
Colombia
Prior art keywords
compositions
mixed
liquid diluent
reducing foaming
solid vaccine
Prior art date
Application number
CONC2017/0004271A
Other languages
English (en)
Inventor
Noel Yves Henri Jean Genin
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of CO2017004271A2 publication Critical patent/CO2017004271A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a una composición de vacuna comprimida estable novedosa que comprende por lo menos un componente antigénico anhidro que comprende un estabilizador susceptible a la espumación cuando la composición se mezcla con diluyente líquido; y una cantidad efectiva de un alcohol de azúcar.
CONC2017/0004271A 2014-10-10 2017-04-27 Un proceso para reducir la espumación de composiciones sólidas de vacuna al mezclarse con un diluente líquido, y composiciones de las mismas CO2017004271A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062180P 2014-10-10 2014-10-10
PCT/US2015/055027 WO2016057978A1 (en) 2014-10-10 2015-10-09 Reduced foaming vaccine compositions

Publications (1)

Publication Number Publication Date
CO2017004271A2 true CO2017004271A2 (es) 2017-09-29

Family

ID=55653887

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0004271A CO2017004271A2 (es) 2014-10-10 2017-04-27 Un proceso para reducir la espumación de composiciones sólidas de vacuna al mezclarse con un diluente líquido, y composiciones de las mismas

Country Status (21)

Country Link
US (6) US10188734B2 (es)
EP (1) EP3203988B1 (es)
JP (2) JP2017534609A (es)
KR (1) KR102652509B1 (es)
CN (1) CN107106667B (es)
AR (1) AR102250A1 (es)
AU (2) AU2015330716B2 (es)
BR (1) BR112017007422A8 (es)
CA (1) CA2964171C (es)
CO (1) CO2017004271A2 (es)
ES (1) ES2895494T3 (es)
HK (1) HK1243341A1 (es)
MX (1) MX2017004679A (es)
MY (1) MY198730A (es)
NZ (1) NZ731296A (es)
PH (1) PH12017500661A1 (es)
PL (1) PL3203988T3 (es)
RU (1) RU2731534C2 (es)
TW (1) TWI745278B (es)
UA (1) UA126057C2 (es)
WO (1) WO2016057978A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019010830A2 (pt) 2016-11-30 2019-10-01 Boehringer Ingelheim Animal Health Usa Inc vacinas atenuadas de influenza suína e métodos de produção e uso das mesmas
CN110308145A (zh) * 2019-07-10 2019-10-08 迪瑞医疗科技股份有限公司 一种沙眼衣原体糖原检测试剂、沙眼衣原体糖原检测试纸条及其制备方法
CN116348595A (zh) * 2020-09-22 2023-06-27 乔治亚大学研究基金公司 传染性支气管炎病毒株dmv1639的减毒分离株

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3184384A (en) * 1961-09-07 1965-05-18 Dow Chemical Co Method of producing brucella abortus vaccine
IL46189A (en) 1974-12-05 1979-01-31 Vineland Lab Ltd Color coded poultry vaccines
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US5178862A (en) 1989-12-01 1993-01-12 Parhelion Corporation Canine distemper virus vaccine and method of preparation
FR2662942B1 (fr) 1990-06-06 1992-09-18 Neway Tsehay Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
ATE197314T1 (de) 1993-02-08 2000-11-15 Bayer Ag Verfahren zum vermehren des das reproduktions- und atemwegs-syndrom verursachenden schweinevirus und dessen verwendung als impfstoff.
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
GB9722682D0 (en) 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
ES2605109T3 (es) 1999-08-24 2017-03-13 Abic Biological Laboratories Ltd. Composición de vacuna y procedimiento de uso de la misma
CN1233418C (zh) * 2001-12-21 2005-12-28 卫广森 鸡传染性支气管炎h120或h52与鸡新城疫二联冻干疫苗耐热冻干保护剂及制备工艺
CN100381463C (zh) * 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
CN1284601C (zh) * 2003-05-22 2006-11-15 维奥（四川）生物技术有限公司 常温稳定的疫苗组合物及其制备方法
CN1261161C (zh) * 2003-11-10 2006-06-28 钱汶光 复方干扰素诱生剂***片
CA2612937C (en) 2005-07-22 2014-05-06 Amgen Inc. Concentrated protein lyophilates, methods, and uses
CN101489587B (zh) * 2006-05-12 2015-05-27 伯哈拉特生物技术国际有限公司 一种可用作疫苗的组合物
UA46896U (ru) * 2009-07-13 2010-01-11 Владимир Николаевич Дзюба Способ изготовления вакцины живой споровой концентрированной против сибирской язвы животных
CN108434089B (zh) * 2010-10-08 2020-06-16 R·P·舍勒科技有限责任公司 使用淀粉的口服疫苗快速溶解剂型
CN102160856A (zh) * 2011-03-28 2011-08-24 南京易海生物科技有限公司 鸡传染性法氏囊病防漏型饮水免疫片及其制备方法
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente

Also Published As

Publication number Publication date
NZ731296A (en) 2018-08-31
JP2017534609A (ja) 2017-11-24
TW201625296A (zh) 2016-07-16
AU2015330716B2 (en) 2018-12-06
HK1243341A1 (zh) 2018-07-13
US20200188519A1 (en) 2020-06-18
CA2964171A1 (en) 2016-04-14
CN107106667A (zh) 2017-08-29
BR112017007422A8 (pt) 2022-07-12
MX2017004679A (es) 2017-08-08
EP3203988A1 (en) 2017-08-16
RU2731534C2 (ru) 2020-09-04
AU2018271395A1 (en) 2018-12-20
AU2018271395B2 (en) 2020-05-14
US10188734B2 (en) 2019-01-29
EP3203988B1 (en) 2021-09-01
US20220241421A1 (en) 2022-08-04
US10610596B2 (en) 2020-04-07
JP2021004246A (ja) 2021-01-14
ES2895494T3 (es) 2022-02-21
US20190151451A1 (en) 2019-05-23
KR20170066532A (ko) 2017-06-14
BR112017007422A2 (pt) 2018-01-16
US20190000978A1 (en) 2019-01-03
US20240042037A1 (en) 2024-02-08
RU2017115776A (ru) 2018-11-12
AU2015330716A1 (en) 2017-05-18
PH12017500661A1 (en) 2017-10-09
US10213509B2 (en) 2019-02-26
PL3203988T3 (pl) 2022-02-14
UA126057C2 (uk) 2022-08-10
RU2017115776A3 (es) 2019-04-11
US20160256554A1 (en) 2016-09-08
WO2016057978A1 (en) 2016-04-14
TWI745278B (zh) 2021-11-11
KR102652509B1 (ko) 2024-03-28
CN107106667B (zh) 2022-03-15
CA2964171C (en) 2023-03-28
AR102250A1 (es) 2017-02-15
MY198730A (en) 2023-09-20

Similar Documents

Publication Publication Date Title
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
CL2018001031A1 (es) Inhibidores de ferroportina novedosos
CL2016002772A1 (es) Composiciones de insulina de rápida acción
BR112017006137A2 (pt) formulação que contém biotensoativo
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
AR095021A1 (es) Composiciones de azúcares mixtos
DOP2016000253A (es) Nuevos compuestos
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112017022209A2 (pt) composição aquosa que compreende éster de ácido omega- aminocarboxílico e álcool graxo e seu uso
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
BR112018006730A2 (pt) método para preparar um composto, substância ou mistura de substância, uso de pelo menos uma substância ou mistura de substância, composição de fragrância, e, agente.
BR112016017776A2 (pt) Formas sólidas de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, composições das mesmas e métodos para seu uso
BR112018007063A2 (pt) processo para produção de uma composição que contém polialquenâmero e seu uso
BR112017008553A2 (pt) processo de extrusão para polipropileno
CO2017004271A2 (es) Un proceso para reducir la espumación de composiciones sólidas de vacuna al mezclarse con un diluente líquido, y composiciones de las mismas
BR112018013058A2 (pt) processo para a preparação de etilenoglicol de açúcares
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
AR097593A1 (es) Proceso para elaborar una composición líquida de limpieza
BR112017008551A2 (pt) processo para extrusão de polipropileno
BR112018006383A2 (pt) composição de limpeza trifásica
BR112018008588A2 (pt) composição, e, processo para preparar uma composição.